证券代码： 002107 证券简称：沃华医药 山东沃华医药科技股份有限公司投资者关系活动记录表 文件编号 2023001 | 投资者关系活动 | □特定对象调研 □ 分析师会议 | | --- | --- | | 类别 | □ 媒体采访 √ 业绩说明会 | | | □ 新闻发布会 □ 路演活动 | | | □ 现场参观 | | | □ 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 投资者网上提问 | | 人员姓名 | | | 时间 | 2023 年 4 月 11 日 (星期二) 下午 15:00~17:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 采用网络远程的方式召开业绩说明会 | | 上市公司接待人 | 1、副董事长、董事会秘书赵彩霞 | | 员姓名 | 2、董事张戈 | | | 3、独立董事俞俊利 | | | 4、总裁曾英姿 | | | 5、副总裁兼财务总监王炯 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了回复： 1、很多患者反应心可舒片疗效很好，公司有何举措让产品在 | | | ...

证券代码：002107 证券简称：沃华医药 公告编号：2023-014 山东沃华医药科技股份有限公司董事会 二〇二三年四月三日 山东沃华医药科技股份有限公司 关于举行 2022 年度业绩网上说明会的通知 山东沃华医药科技股份有限公司（以下简称公司）定于2023年4月11 日（星期二） 15:00–17:00 举行2022年度业绩网上说明会。本次业绩说 明会采用网络远程的方式召开，投资者可登陆全景网"投资者关系互动 平台"（http://ir.p5w.net）参与本次说明会。 出席公司2022年度业绩网上说明会的人员有：副董事长、董事会秘 书赵彩霞女士，董事张戈先生，独立董事俞俊利先生，总裁曾英姿女士， 副总裁、财务总监王炯先生。 欢迎广大投资者积极参与。 特此公告。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 ...

Financial Performance - The company's operating revenue for 2022 was CNY 1,014,818,455.50, representing a 7.65% increase compared to CNY 942,674,553.55 in 2021[23]. - The net profit attributable to shareholders decreased by 34.28% to CNY 107,385,865.65 from CNY 163,392,002.72 in the previous year[23]. - The net profit after deducting non-recurring gains and losses was CNY 104,772,706.39, down 33.40% from CNY 157,328,113.26 in 2021[23]. - The net cash flow from operating activities was CNY 185,258,732.05, a decrease of 7.43% compared to CNY 200,119,233.17 in 2021[23]. - Basic earnings per share fell by 32.14% to CNY 0.19 from CNY 0.28 in the previous year[23]. - The total assets at the end of 2022 were CNY 1,099,991,311.86, a decrease of 5.26% from CNY 1,161,092,124.65 at the end of 2021[23]. - The net assets attributable to shareholders decreased by 9.04% to CNY 746,500,239.28 from CNY 820,716,496.07 in 2021[23]. - The weighted average return on net assets was 14.10%, down from 20.71% in the previous year, a decrease of 6.61%[23]. Market Trends and Opportunities - The medical industry is expected to continue growing due to increasing healthcare demands driven by an aging population and rising chronic disease rates[32]. - The proportion of healthcare spending in China is expected to increase, with the basic medical insurance fund's total income growing by 15.6% in 2021[33]. - The aging population is projected to exceed 400 million by 2035, leading to a significant increase in demand for medical services and products[36]. - The prevalence of chronic non-communicable diseases is rising, with a reported chronic disease rate of 23%, indicating a growing market for long-term medication and healthcare services[36]. - The traditional Chinese medicine (TCM) industry has a broad prospect, supported by the government's continuous policy backing and the unique advantages of TCM in treating chronic diseases[38][40]. Product Development and R&D - The company is committed to enhancing its R&D capabilities, particularly in traditional Chinese medicine, and plans to deepen collaborations with research institutions to develop new products[55]. - The company has developed a proprietary traditional Chinese medicine, Brain Blood Smooth Oral Liquid, which is a unique patented product for treating acute cerebral hemorrhage and early recovery phases[70]. - The company has received multiple funding supports for Brain Blood Smooth Oral Liquid from national projects, including the National Torch Program and key projects in Shandong Province[70]. - The company has established a collaborative research and development model with multiple domestic research institutions, enhancing innovation in traditional Chinese medicine[76]. - The company has implemented a detailed intellectual property protection strategy to ensure the long-term stability and continuous investment in its exclusive products[137]. Marketing and Sales Strategies - The company has established a comprehensive marketing system targeting various terminal markets, enhancing its operational efficiency and brand influence[146]. - The marketing team has expanded its academic promotion capabilities by attracting experienced external marketing talents and enhancing training for existing staff[107]. - The company has implemented a budget-based specialized clinical academic promotion model, enhancing direct engagement with healthcare professionals to boost product demand[86]. - The company has signed a cooperation agreement with Shandong Jiuzhoutong Pharmaceutical Co., Ltd. to promote e-commerce strategies nationwide[102]. - The company is focusing on academic promotion and process management to stabilize operational performance amid market challenges[100]. Operational Challenges - Raw material prices have surged significantly, with hawthorn up 41.4%, salvia miltiorrhiza up 27.2%, and rehmannia glutinosa up 170.3% compared to 2021, increasing operational pressure[53]. - The ongoing reform of the medical insurance payment system poses challenges for clinical use, particularly in hospitals, necessitating effective marketing strategies[50]. - The company has faced rising labor costs and a significant short-term labor shortage due to market conditions[52]. - Strengthened regulatory enforcement and compliance requirements are expected to increase operational costs for smaller firms, benefiting established companies with robust compliance systems[51]. Future Outlook - The company aims to achieve stable and sustainable growth in sales revenue and profit as its main operational goal for 2023[190]. - The company will focus on the development of its four major proprietary medical insurance pillar products, which are crucial for driving overall sales revenue[194]. - The company plans to enhance its marketing reform efforts, which have already shown promising results, to further boost performance in 2023[193]. - The company will prioritize resource allocation to strengthen the development of its proprietary products, ensuring they become leading brands in their respective therapeutic areas[194]. - The company will explore new marketing strategies in response to market changes, particularly in the antiviral and cold medicine sectors, to expand profit margins[198].

附件二：投资者关系活动记录表格式 证券代码：002107 证券简称：沃华医药 山东沃华医药科技股份有限公司投资者关系活动记录表 编号：2012002 | --- | --- | --- | |----------------|------------------------------|--------------------------------------------------| | | | | | 投资者关系活动 | | 特定对象调研 □分析师会议 | | 类别 | □ 媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 中信建投 医药行业首席分析师 贺菊颖女士 | | 人员姓名 | | | | 时间 | 2020 年 5 月 11 日 | 14:00 | | 地点 | 公司会议室 | | | 上市公司接待人 | | 副董事长、董事会秘书赵彩霞女士 | | 员姓名 | 董事张戈先生 | | | | 证券事务代表庞静杰女士 | | | 投资者关系活动 | 1 、请问公司 ...

附件二：投资者关系活动记录表格式 证券代码：002107 证券简称：沃华医药 山东沃华医药科技股份有限公司投资者关系活动记录表 编号：2020001 | --- | --- | --- | |----------------|-----------------------------|-----------------------------------------------| | | | | | 投资者关系活动 | | 特定对象调研 □分析师会议 | | 类别 | □ 媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 信达证券 医药行业分析师 周贤珮女士 | | 人员姓名 | | | | 时间 | 2020 年 5 月 8 日 | 14:00 | | 地点 | 公司会议室 | | | 上市公司接待人 | | 副董事长、董事会秘书赵彩霞女士 | | 员姓名 | 董事张戈先生 | | | | 证券事务代表庞静杰女士 | | | 投资者关系活动 | 1 、公司总裁 | 2019 ...

附件二：投资者关系活动记录表格式 证券代码：002107 证券简称：沃华医药 山东沃华医药科技股份有限公司投资者关系活动记录表 编号：2012005 | --- | --- | --- | |----------------|--------------------------------|--------------------------------------------------| | | | | | 投资者关系活动 | | 特定对象调研 □分析师会议 | | 类别 | □ 媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 信达证券 投资经理 孟阳女士 | | | 人员姓名 | | | | 时间 | 2020 年 5 月 27 日 | 14:00 | | 地点 | 公司会议室 | | | 上市公司接待人 | 副董事长、董事会秘书赵彩霞女士 | | | 员姓名 | 董事张戈先生 | | | | 证券事务代表庞静杰女士 | | | 投资者关系活动 | | 1、公司的产品结构 ...

附件二：投资者关系活动记录表格式 证券代码：002107 证券简称：沃华医药 山东沃华医药科技股份有限公司投资者关系活动记录表 编号：2012004 | --- | --- | --- | |----------------|------------------------------|--------------------------------------------------| | | | | | 投资者关系活动 | | 特定对象调研 □分析师会议 | | 类别 | □ 媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 天风证券 医药行业首席分析师 杨烨辉先生 | | 人员姓名 | | | | 时间 | 2020 年 5 月 13 日 | 16:00 | | 地点 | 公司会议室 | | | 上市公司接待人 | | 副董事长、董事会秘书赵彩霞女士 | | 员姓名 | 董事张戈先生 | | | | 证券事务代表庞静杰女士 | | | 投资者关系活动 | 1 | 、之前 ...

附件二：投资者关系活动记录表格式 证券代码：002107 证券简称：沃华医药 山东沃华医药科技股份有限公司投资者关系活动记录表 编号：2020007 | --- | --- | --- | |----------------|-----------------------------|----------------------------------------------------------------| | | | | | 投资者关系活动 | | 特定对象调研 □分析师会议 | | 类别 | □ 媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 北京天蝎座资产管理有限公司组织的投资者 | | 人员姓名 | | | | 时间 | 2020 年 8 月 5 日 | 9:00 | | 地点 | 公司会议室 | | | 上市公司接待人 | | 副董事长、董事会秘书赵彩霞女士 | | 员姓名 | 董事张戈先生 | | | | 证券事务代表庞静杰女士 | | | 投资者关系活动 ...

Financial Performance - In 2019, the company achieved an annual revenue of 860.29 million yuan, a year-on-year increase of 11.09% [3] - The net profit attributable to shareholders was 95.80 million yuan, with a year-on-year growth of 109.85% [4] - In Q1 2020, the company reported a revenue of 218.05 million yuan, a year-on-year increase of 16.34% [4] - The net profit attributable to shareholders for Q1 2020 was 44.13 million yuan, showing a year-on-year increase of 226.07% [4] - For the first half of 2020, the expected net profit attributable to shareholders is between 81.31 million yuan and 96.94 million yuan, representing a year-on-year growth of 160%-210% [5] Strategic Initiatives - The company focuses on four exclusive medical insurance pillar products to drive sales growth [5] - Emphasis on digital transformation and refined management to enhance operational efficiency [12] - The company has adopted a multi-channel marketing strategy, including professional clinical promotion, agency recruitment, and OTC retail [9][10] Market Opportunities - The company capitalized on policy opportunities related to chronic disease medications, particularly during the pandemic [4][11] - The removal of the "△" mark from the medical insurance directory for certain products has opened new market opportunities [18] - The market for the company's products, especially 荷丹片/胶囊, is expected to grow significantly due to its potential user base among patients with high blood pressure, blood sugar, and cholesterol [17][18] Cost Management - The company has implemented measures to reduce marketing costs while increasing efficiency through digital channels [12][14] - Sales expenses are projected to slightly increase in Q2 2020 compared to Q1 but will still show a year-on-year decline [14] Future Outlook - The company aims to maintain steady revenue growth through its established marketing system and product structure [15] - Plans for potential mergers and acquisitions focus on introducing unique traditional Chinese medicine products that align with existing offerings [19]

附件二：投资者关系活动记录表格式 证券代码：002107 证券简称：沃华医药 山东沃华医药科技股份有限公司投资者关系活动记录表 编号：2020008 | --- | --- | --- | --- | |----------|--------------------------------|-------|---------------------------------------------------------| | | | | | | 投资者关 | | | 特定对象调研 □分析师会议 | | 系活动类 | □媒体采访 □业绩说明会 | | | | 别 | □ 新闻发布会 □路演活动 | | | | | □现场参观 | | | | | □ | | 其他 （请文字说明其他活动内容） | | 参与单位 | 华融证券 医药行业分析师 张科然 | | | | 名称及人 | 华泰证券 研究员 张云逸 | | | | 员姓名 | | | | | 时间 | 2020 年 9 月 14 日 | | 13:00 | | 地点 | | | 辽宁康辰药业有限公司 厂区及会议室 | | 上市公司 | | | 董事会执行委员会 ...